Treatment of Retinal Pigment Epithelial Detachment
Article Sidebar
Main Article Content
Abstract
Anatomical separation of the retinal pigment epithelium from the Bruch membrane is defined as retinal pigment epithelial detachment (PED) andit is classified as drusenoid, serous, and vascularized. Vascularized PED is mostly associated with choroidal neovascularmembrane due to age-related macular degeneration and the risk of vision loss is high in this situation. Studies show that all of baseline values including BCVA, PED height, subretinal fluid, central macular thickness, PED volume, vertical dimension, presence of coincident macular pathology, reflectivity and morphology on optical coherence tomography have prognostic importance. Current treatment protocols mainly based on intravitreal injection of anti-vascular endothelial growth factor (VEGF).Even the bevacizumab was the first anti-VEGF that was used for treatment in PED, there are several reports show the insufficiency of bevacizumab. In treatment-naïve eyes, both of ranibizumab and aflibercepthave similar effect in vascularized PED. In treatment-resistant eyes, high dose bevacizumab or switching therapy of anti-VEGF procedures can be effective when considering of all cases, aflibercept seems more effective than other options.We aimed in this manuscript, to give a general information about different characteristics of PEDs and to investigate the treatment strategies in the light of current literature.
Article Details
Copyright (c) 2018 Altintas AGK, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Mrejen S, Sarraf D, Mukkamala SK, Freund KB. Multimodal imaging of pigment epithelial detachment: a guide to evaluation. Retina. 2013; 33: 1735-1762. Ref: https://goo.gl/3PMfj4
Sarks JP, Sarks SH, Killingsworth MC. Evolution of soft drusen in age-related macular degeneration. Eye (Lond). 1994; 8: 269-283. Ref.: https://goo.gl/KyUxNF
Schmitz-Valckenberg S, Fleckenstein M, Scholl HP, Holz FG. Fundus autofluorescence and progression of age-related macular degeneration. Surv Ophthalmol. 2009; 54: 96-117. Ref.: https://goo.gl/KXVte5
Arnold JJ, Quaranta M, Soubrane G, Sarks SH, Coscas G. Indocyanine green angiography of drusen. Am J Ophthalmol. 1997; 124: 344-356. Ref.: https://goo.gl/HUxH5g
Casswell AG, Kohen D, Bird AC. Retinal pigment epithelial detachments in the elderly: classification and outcome. Br J Ophthalmol. 1985; 69: 397-403. Ref.: https://goo.gl/KhUZFh
Hartnett ME, Weiter JJ, Garsd A, Jalkh AE. Classification of retinal pigment epithelial detachments associated with drusen. Graefes Arch Clin Exp Ophthalmol. 1992; 230: 11-19. Ref.: https://goo.gl/Wtr1o6
Lommatzsch A, Heimes B, Gutfleisch M, Spital G, Zeimer M, et al. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye (Lond). 2009; 23: 2163-2168. Ref.: https://goo.gl/26chZh
Laatikainen L, Hoffren M. Long-term follow-up study of non- senile detachment of the retinal pigment epithelium. Eur J Ophthalmol. 1991; 1: 79-84. Ref.: https://goo.gl/SkBViT
Karadimas P, Bouzas EA. Fundus auto fluorescence imaging in serous and drusenoid pigment epithelial detachments associated with age-related macular degeneration. Am J Ophthalmol. 2005; 140: 1163-1165. Ref.: https://goo.gl/8FpL2E
Spaide RF. Enhanced depth imaging optical coherence tomography of retinal pigment epithelial detachment in age-related macular degeneration. Am J Ophthalmol. 2009; 147: 644-652. Ref.: https://goo.gl/D28pK5
Subfoveal neovascular lesions age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study Group. Arch Ophthalmol. 1991; 109: 1242-1257. Ref.: https://goo.gl/eQi13W
Yannuzzi LA, Slakter JS, Sorenson JA, Guyer DR, Orlock DA. Digital indocyanine green videoangiography and choroidal neovascularization. Retina.1992; 12: 191-223. Ref.: https://goo.gl/YUCeuh
Gass JD. Drusen and disciform macular detachment and degeneration. Arch Ophthalmol.1973; 90: 206-217. Ref.: https://goo.gl/pTuYBs
Chang LK, Flaxel CJ, Lauer AK, Sarraf D. RPE tears after pegaptanib treatment in age-related macular degeneration. Retina. 2007; 27: 857-863. Ref.: https://goo.gl/jd1oRd
Lam D, Semoun O, Blanco-Garavito R, Jung C, Nguyen DT, et al. Wrinkled vascularized retinal pigment epithelium detachment prognosis after intravitreal anti-VEGF therapy. Retina. 2017. Ref.: https://goo.gl/fccRT5
Baba T, Kitahashi M, Kubota-Taniai M, Oshitari T, Yamamoto S. Two-year course of subfoveal pigment epithelial detachment in eyes with age-related macular degeneration and visual acuity better than 20/40. Ophthalmologica. 2012; 228: 102-109. Ref.: https://goo.gl/pTohtv
Brancato R, Introini U, Bolognesi G, Pacelli G, Trabucchi G, et al. ICGA-guided laser photocoagulation of occult choroidal neovascularization in age-related macular degeneration. Indocyanine green angiography. Retina. 2000; 20: 134-142. Ref.: https://goo.gl/66A4Zw
Yüksel H, Türkcü FM, Sahin A, Sahin M, Cinar Y, et al.One year results of anti-VEGF treatment in pigment epithelial detachment secondary to macular degeneration. Arq Bras Oftalmol. 2013; 76: 209-211. Ref.: https://goo.gl/cZewgP
Ach T, Hoeh AE, Ruppenstein M, Kretz FT, Dithmar S. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration. Retina. 2010; 30: 1420-1425. Ref.: https://goo.gl/ZDXuuq
Lee DK, Kim SH, You YS, Kwon OW. High Dose Intravitreal Bevacizumab for Refractory Pigment Epithelial Detachment in Age-related Macular Degeneration. Korean J Ophthalmol. 2016; 30: 265-271. Ref.: https://goo.gl/rDrx7e
Chevreaud O, Oubraham H, Cohen SY, Jung C, Blanco-Garavito R, et al. Ranibizumab for vascularized pigment epithelial detachment: 1-year anatomic and functional results. Graefes Arch Clin Exp Ophthalmol. 2017; 255: 743-751. Ref.: https://goo.gl/4fJCBL
Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012; 119: 2537-2548. Ref.: https://goo.gl/c8ibsz
Vaze A, Nguyen V, Daien V, Arnold JJ, Young SH, et al. Ranibizumab and aflibercept for the treatment of pigment epithelial detachment in neovascular age-related macular degeneration: Data from an Observational Study. Retina. 2017. Ref.: https://goo.gl/CbU1hP
Balaskas K, Karampelas M, Horani M, Hotu O, Keane P, et al. Quantitative analysis of pigment epithelial detachment response to different anti-vascular endothelial growth factor agents in wet age-related macular degeneration. Retina. 2017; 37: 1297-1304. Ref.: https://goo.gl/gGCLwD
Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent sub-foveal fluid despite previous treatments with ranibizumab in patients with neovascula rage-related macular degeneration. Retina. 2013; 33: 1605-1612. Ref.: https://goo.gl/1YiS5U
Chan CK, Jain A, Sadda S, Varshney N. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-relatedmacular degeneration (an AmericanOphthalmologicalSocietythesis). Trans Am Ophthalmol Soc. 2014; 112: 160-198. Ref.: https://goo.gl/he65fj
deMassougnes S, Dirani A, Mantel I. Good visual outcome at 1 year in neovascular age-related macular degeneration with pigment epithelium detachment: Factors Influencing the Treatment Response. Retina. 2018. 38: 717-724. Ref.: https://goo.gl/yCFMw7
Broadhead GK, Hong T, Zhu M, Li H, Schlub TE. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration. Retina. 2015; 35: 975-981. Ref.: https://goo.gl/ejVYW2
He L, Silva RA, Moshfeghi DM, Blumenkranz MS, Leng T. Aflibercept for the treatment of retinal pigment epithelial detachments. Retina. 2016; 36: 492-498. Ref.: https://goo.gl/TsWakB
Zinkernagel MS, Wolf S, Ebneter A. Fluctuations in pigment epithelial detachment and retinal fluid using a bimonthly treatment regimen with aflibercept for neovascular age-related macular degeneration. Ophthalmologica. 2016; 235: 42-48. Ref.: https://goo.gl/gXKB5D
Chen X, Al-Sheikh M, Chan CK, Hariri AH, Abraham P, et al. Type 1 versus type 3 neovascularization in pigment epithelial detachments associated with age-related macular degeneration after anti-vascular endothelial growth factor therapy: A Prospective Study. Retina. 2016; 36: 50-64. Ref.: https://goo.gl/xreoH3
Kim K, Kim ES, Kim Y, Yang JH, Yu SY, et al. Outcome of intravitreal aflibercept for refractory pigment epithelial detachment with or without subretinal fluid and secondary to age-related macular degeneration. Retina. 2017. Ref.: https://goo.gl/ZaLU51
Treumer F, Wienand S, Purtskhvanidze K, Roider J, Hillenkamp J. The role of pigment epithelial detachment in AMD withs submacular hemorrhage treated with vitrectomy and subretinal co-application of rtPAand anti-VEGF. Graefes Arch Clin Exp Ophthalmol. 2017; 255: 1115-1123. Ref.: https://goo.gl/EWmZRB
Doguizi S, Ozdek S. Pigment epithelial tears associated with anti-VEGF therapy: incidence, long-term visual outcome, and relationship with pigment epithelial detachment in age-related macular degeneration. Retina. 2014; 34: 1156-1162. Ref.: https://goo.gl/bBdxkX
Chiang A, Chang LK, Yu F, Sarraf D. Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis. Retina. 2008; 28: 1265-1269. Ref.: https://goo.gl/BwhsNe